Bayer
Illumina Adds CDx Indication to European TruSight Oncology Test for NTRK Gene Fusion Detection
The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's Vitrakvi (larotrectinib).
Precision Cancer Consortium Launches With Bayer, GSK, Roche, Novartis as Founding Members
The organization of pharmaceutical and biotechnology firms aims to increase access to genomic testing for cancer patients.
In Brief This Week: MDxHealth, Co-Diagnostics, HTG Molecular Diagnostics, Immunovia, and More
News items for the in vitro diagnostics industry for the week of Nov. 8, 2021.
Bayer, Veracyte to Identify Therapy-Resistant Thyroid Cancer Patients
Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.
Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.